Synthesis of diindolylmethanes and indolo[3,2-b]carbazoles, compounds formed thereby, and pharmaceutical compositions containing them
Described is a method to make diindolylmethanes and indolyl/pyrrolylmethanes, The method includes the steps of contacting an ether comprising an arylpropargyl moiety and an amine-protected, substituted or unsubstituted aniline moiety with a substituted or unsubstituted indol or a substituted or unsubstituted pyrrole, in the presence of a metal-containing catalyst, for a time and at a temperature to cause an annulation/arylation cascade reaction that yields a diindolylmethane or a indolyl/pyrrolylmethane. The resulting compounds are effective to modulate activity of arylhydrocarbon receptors, to inhibit activity of PCSK9, and to stimulate secretion of glucagon-like peptide 1 in mammals.
1. A pharmaceutical composition comprising an amount of a compound of formula:
wherein R 1 and R 1 ′ are independently hydrogen or alkyl, provided that at least one of R 1 and R 1 ′ is hydrogen;
R is selected from the group consisting of halogen, hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl; and
R 3 , R 4 , R 5 , R 6 , R 7 , R 3 ′, R 4 ′, R 5 ′, R 6 ′, and R 7 ′ are independently selected from hydrogen, halogen, hydroxyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl;
or a pharmaceutically suitable salt thereof;
in combination with a pharmaceutically suitable carrier;
wherein the amount is effective to modulate activity of arylhydrocarbon receptors in mammals, or the amount is effective to inhibit activity of PCSK9 in mammals, or the amount is effective to stimulate secretion of glucagon-like peptide 1 in mammals.
2. The pharmaceutical composition of claim 1 , wherein R 1 and R 1 ′ are hydrogen.
3. The pharmaceutical composition of claim 1 , wherein one of R 1 or R 1 ′ is hydrogen and the other of R 1 or R 1 ′ is alkyl.
4. The pharmaceutical composition of claim 1 , wherein at least one of R 3 , R 4 , R 5 , R 6 , R 7 , R 3 ′, R 4 ′, R 5 ′, R 6 ′, and R 7 ′ is not hydrogen.
5. The pharmaceutical composition of claim 1 , wherein at least one of R 3 , R 4 , R 5 , R 6 , R 7 , R 3 ′, R 4 ′, R 5 ′, R 6 ′, and R 7 ′ is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, and substituted or unsubstituted aryl.
6. A method to inhibit activity of proprotein convertase subtilisin/kexin type 9 (PCSK9) in mammals, the method comprising administering to the mammal a PCSK9 inhibitory-effective amount of a compound of formula:
wherein R 1 and R 1 ′ are independently hydrogen or alkyl;
R is selected from the group consisting of halogen, hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl; and
R 3 , R 4 , R 5 , R 6 , R 7 , R 3 ′, R 4 ′, R 5 ′, R 6 ′, and R 7 ′ are independently selected from hydrogen, halogen, hydroxyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl;
R 3 ′ may additionally be selected from acyl (—C(═O)H);
or a pharmaceutically suitable salt thereof.
7. A method to stimulate secretion of glucagon-like peptide 1 (GLP-1) in mammals, the method comprising administering to the mammal a GLP-1 secretion stimulative-effective amount of a compound of formula:
wherein R 1 and R 1 ′ are independently hydrogen or alkyl;
R is selected from the group consisting of halogen, hydroxyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl; and
R 3 , R 4 , R 5 , R 6 , R 7 , R 3 ′, R 4 ′, R 5 ′, R 6 ′, and R 7 ′ are independently selected from hydrogen, halogen, hydroxyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl;
R 3 ′ may additionally be selected from acyl (—C(═O)H);
or a pharmaceutically suitable salt thereof.